Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Montesinos P, et al. Among authors: huang f. Leukemia. 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5. Epub 2020 Mar 16. Leukemia. 2021. PMID: 32203138 Free PMC article. Clinical Trial.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Talpaz M, et al. Among authors: huang f. N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229. N Engl J Med. 2006. PMID: 16775234 Free article. Clinical Trial.
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J, Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G. Cloos J, et al. Among authors: huang f. J Vis Exp. 2018 Mar 5;(133):56386. doi: 10.3791/56386. J Vis Exp. 2018. PMID: 29553571 Free PMC article.
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Kearns P, Zwaan CM, Reinhardt D, Gibson B, Moreno L, Nysom K, Nakahara S, Huang F, Zhou W, Parasrampuria DA, Nemat S. Kearns P, et al. Among authors: huang f. Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7. Br J Haematol. 2019. PMID: 30847896 Free article. Clinical Trial. No abstract available.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. Steensma DP, et al. Among authors: huang f. J Clin Oncol. 2021 Jan 1;39(1):48-56. doi: 10.1200/JCO.20.01895. Epub 2020 Oct 27. J Clin Oncol. 2021. PMID: 33108243 Clinical Trial.
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H 3rd, Loriaux MM, Tognon CE, Lo P, Tyner JW, Fan G, McWeeney SK, Druker BJ, Lind EF. Lamble AJ, et al. Among authors: huang f. Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14331-14341. doi: 10.1073/pnas.1916206117. Epub 2020 Jun 8. Proc Natl Acad Sci U S A. 2020. PMID: 32513686 Free PMC article.
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Mascarenhas J, et al. Among authors: huang f. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17. J Clin Oncol. 2021. PMID: 34138638 Clinical Trial.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: huang f. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38580254
11,424 results
You have reached the last available page of results. Please see the User Guide for more information.